Cognitive impairment (CI) is an important symptomatic domain for many mental disorders including depression, anxiety, bipolar disorder, and schizophrenia. CI can be also developed after various other diseases such as type 2 diabetes mellitus (T2DM), chronic pain, and neurodegenerative diseases. CI contributes significantly to the occupational and functional disability of the patients. Out of many subdomains of cognition, the following ones are the most vulnerable during the progression of the diseases, including learning and memory, executive functioning, processing speed, and attention and concentration. Till now, there still lacks solid evidence supporting the efficacy of medication to ameliorate CI mainly due to the unrevealed underlying mechanisms of CI. Meanwhile, the previous study shows that improving performance across cognitive domains in individuals with mental disorders may improve psychosocial function, workplace function, quality of life, and other patient-reported outcomes. Some research has attempted to elucidate the underlying neuro-mechanism for CI, for example, neurovascular coupling disorder and dysbacteriosis are suggested to contribute to CI in different diseases such as migraine, T2DM and Alzheimer's Disease (AD). However, the underlying mechanisms for CI are yet to be fully understood and the treatments are far from clinical satisfaction.
In recent years, new techniques used in radiomics, proteomics, and genomics have offered potential biomarkers for understanding and potentially treating CI. By using radiomics tools, the high-dimensional neuroimaging features can offer applicable therapeutic instructions for CI diagnoses. By using proteomics and genomics, networks with pivotal lncRNA, miRNA, and key proteins have been used to investigate the CI mechanisms to provide guidance for clinical decisions. Utilizing these advanced techniques, growing number of studies on CI have been performed with exciting outcomes. However, this is still largely research in progress and more thorough and in-depth studies are much needed.
Therefore, this research topic focuses on the further exploration of the neurobiological underpinnings and the potential pharmacological treatments of CI, associated with mental disorders. The sub-themes of this Research Topic include but are not limited to the following:
- Biomarkers obtained using genomics and proteomics techniques
- Functional and connectivity neuroimaging as a tool for identifying CI biomarkers
- Networks and neurocircuits derived from animal or human studies underpinning CI
- Genomics and proteomics-derived novel potential pharmacotherapeutics for CI
Cognitive impairment (CI) is an important symptomatic domain for many mental disorders including depression, anxiety, bipolar disorder, and schizophrenia. CI can be also developed after various other diseases such as type 2 diabetes mellitus (T2DM), chronic pain, and neurodegenerative diseases. CI contributes significantly to the occupational and functional disability of the patients. Out of many subdomains of cognition, the following ones are the most vulnerable during the progression of the diseases, including learning and memory, executive functioning, processing speed, and attention and concentration. Till now, there still lacks solid evidence supporting the efficacy of medication to ameliorate CI mainly due to the unrevealed underlying mechanisms of CI. Meanwhile, the previous study shows that improving performance across cognitive domains in individuals with mental disorders may improve psychosocial function, workplace function, quality of life, and other patient-reported outcomes. Some research has attempted to elucidate the underlying neuro-mechanism for CI, for example, neurovascular coupling disorder and dysbacteriosis are suggested to contribute to CI in different diseases such as migraine, T2DM and Alzheimer's Disease (AD). However, the underlying mechanisms for CI are yet to be fully understood and the treatments are far from clinical satisfaction.
In recent years, new techniques used in radiomics, proteomics, and genomics have offered potential biomarkers for understanding and potentially treating CI. By using radiomics tools, the high-dimensional neuroimaging features can offer applicable therapeutic instructions for CI diagnoses. By using proteomics and genomics, networks with pivotal lncRNA, miRNA, and key proteins have been used to investigate the CI mechanisms to provide guidance for clinical decisions. Utilizing these advanced techniques, growing number of studies on CI have been performed with exciting outcomes. However, this is still largely research in progress and more thorough and in-depth studies are much needed.
Therefore, this research topic focuses on the further exploration of the neurobiological underpinnings and the potential pharmacological treatments of CI, associated with mental disorders. The sub-themes of this Research Topic include but are not limited to the following:
- Biomarkers obtained using genomics and proteomics techniques
- Functional and connectivity neuroimaging as a tool for identifying CI biomarkers
- Networks and neurocircuits derived from animal or human studies underpinning CI
- Genomics and proteomics-derived novel potential pharmacotherapeutics for CI
